The Medical War on Cancer

That sentence deserves a moment before the argument begins. It is not a rhetorical flourish. It is a precise description of what happens to the human body when it is subjected to the three pillars of modern oncology. The tumor forms because the body cannot dissolve and remove dead cells. Chemotherapy kills cells by the billion, leaving behind a vastly expanded field of dead cellular matter. Radiation burns cells to death and permanently prevents their regeneration, creating new dead zones in tissue that was functional before treatment began. Biopsy and lymph node removal eliminate the very drainage infrastructure the body was using to process the tumor site, forcing the accumulated toxicity to find a new location, which oncology then calls metastasis. The treatment creates more of the exact condition that caused the cancer. Not as a side effect, not as an acceptable trade-off. As a direct and documented consequence of how each intervention works.

This is not a fringe argument. It is the logical conclusion of following each treatment to its biological outcome, and it is what Aajonus Vonderplanitz spent the better part of four decades trying to communicate, first from personal experience that nearly killed him and did disable him for years, and then from clinical work with thousands of cancer patients. Understanding why the treatments make the terrain worse requires understanding what the terrain is and what caused the tumor in the first place. The tumor is a mass of dead cells that the body could not dissolve and remove. The body built the tumor to contain that mass, to wall it off from functional tissue, and where a malignant tumor exists, to deploy specialized cancer cells as solvents to begin the dissolution process. Disrupt that process, add more dead cellular matter, destroy the lymphatic drainage capacity, and the body does not recover from cancer. It accumulates more of the same material in more locations. That is what the data shows. That is what Aajonus documented. And that is what several independent lines of research, conducted entirely within the conventional scientific literature, support.

The most important study most oncologists would prefer their patients never encounter was published in 2004 in the journal Clinical Oncology. Morgan and colleagues conducted a systematic analysis of the contribution of chemotherapy to five-year survival across twenty-two different cancer types in Australia and the United States. Their finding was precise and devastating: chemotherapy contributed approximately 2.3 percent to overall five-year survival rates. Not 50 percent. Not 30 percent. Two point three. The vast majority of cancer survival, the analysis found, was attributable to surgery, spontaneous remission, and the natural course of the disease. Chemotherapy, the treatment that generates hundreds of billions of dollars in annual pharmaceutical revenue, the treatment that Aajonus described as a poison that kills one cancer cell for every billion healthy cells it destroys, contributed less than three percentage points to the outcome that oncologists use to define success.

This finding was not published by alternative medicine advocates. It appeared in a peer-reviewed oncology journal written by researchers operating entirely within the conventional medical system. And yet the number has had virtually no effect on prescribing practice, treatment protocols, or patient-facing communication. Patients are still told that chemotherapy is the standard of care. They are still told that refusing it is irrational and dangerous. They are rarely told that the data supporting its efficacy across most cancer types is thin enough to fit inside a rounding error.

The broader pattern was documented even earlier. In 1997, Bailar and Gornik published a landmark analysis in the New England Journal of Medicine examining age-adjusted cancer mortality data across the full span of the so-called "war on cancer." Their conclusion was that despite decades of treatment advances, despite hundreds of billions of dollars in research spending, despite the proliferation of chemotherapy protocols and radiation technologies and surgical interventions, age-adjusted cancer mortality had not significantly declined at the population level. The "war on cancer," declared by President Nixon in 1971, had produced no measurable reduction in the rate at which Americans died from cancer when age was properly controlled. What had changed was earlier detection, which creates the appearance of improved survival (if you know about a cancer two years earlier, you appear to survive two years longer even if nothing changes about the disease course). What had not changed was the underlying death rate.

Aajonus's observation about this statistical architecture was blunt: "The doctors say, oh, we cured this cancer. It's been gone for five years. You had it in ten other places in your body, but we cured you of cancer." The five-year mark is not biologically significant. It is legally significant. Oncology defines a cure as the absence of detectable disease at the five-year point, because, as Aajonus documented from his own research, cancer most frequently reappears between year five and year seven post-treatment. The five-year window closes just before the statistical majority of relapses occur. Patients are counted as cured, the oncologist collects the credit, and when the metastasis appears in year six, it is classified as a new cancer. The original treatment is not implicated. The numbers stay clean.

The lymphatic system is the body's primary processing infrastructure for dead cellular material. Every cancer will contain cancer cells in the lymph, because the lymph glands are the sites where the body is actively breaking down the tumor debris. Finding cancer cells in a lymph node is not evidence of spreading cancer. It is evidence of a functioning lymphatic system doing exactly what it was designed to do. Aajonus made this point repeatedly and with some urgency, because the routine practice of removing lymph nodes at the time of biopsy or tumor surgery represents, in his framework, the deliberate elimination of the body's primary containment and processing mechanism.

His account of his mother's breast cancer diagnosis illustrates what this looks like in practice. She was scheduled for a lumpectomy with the removal of eleven lymph glands, followed by pinpoint radiation. Aajonus's response was not panic but a series of functional questions: What do lymph glands do? They clean dead cells and waste from the body. They are the immune architecture at the tissue level. Remove eleven of them from the breast area and ask: where does the toxicity go when you breathe in something carcinogenic? Where does the dead cellular debris migrate when the local lymphatic drainage is gone? Into the lungs, the throat, the adjacent tissue, where new tumors will form to contain what the missing lymph glands can no longer process. "You lop off women's breasts," Aajonus said in one workshop, "and take out their lymph glands, and guess what? You don't have the lymph glands to do the work anymore. So now you're likely to get cancer in your lungs, in your throat, somewhere around here. Because you don't have what you need to clean the body."

The surgical literature offers an uncomfortable parallel. Demicheli and colleagues, publishing in the Annals of Oncology in 2008, documented evidence that surgical removal of primary tumors can actually accelerate metastatic growth in some cases. The mechanism proposed is disruption of the body's containment strategy: the primary tumor site, and the lymphatic drainage infrastructure around it, may be actively preventing the migration of tumor-forming material elsewhere in the body. Remove it surgically, and the containment fails. What oncology calls metastasis following surgery may in some cases be exactly what Aajonus described: not the cancer spreading, but the body's drainage capacity being eliminated, forcing accumulated toxicity to form new collections in whatever tissue can contain it.

Aajonus's position on lymph node removal was direct: swollen lymph nodes mean the nodes are working. Working nodes are not diseased nodes. They are responding to the load placed on them. Leave them intact. Even in cases where a single lymph node is hardened and engorged beyond function, the surrounding nodes that are swollen and processing should be preserved. In a workshop discussion of a case involving a tumor on the scapula, Aajonus spent three weeks persuading a surgeon to remove only the tumor and spare the lymph glands. "I made him think," he said. "If the lymph gland is responsible for cleaning the body, even cancer, isn't it the best idea to leave every lymph gland you can in the body? Because then it will help dissolve these tumors, these dead cells, and get rid of this cancer easier. If you remove them, where's the cancer going to go?"

It is worth taking seriously the scale of what Aajonus described when he characterized chemotherapy as a poison. He did not mean that it was unpleasant or that it had side effects. He meant that its mechanism of action, the thing it actually does at the cellular level, is fundamentally incompatible with healing. "Chemotherapy is a poison that kills more cells and increases the likelihood of cancer," he stated plainly. "Radiation keeps cells from regenerating, burns them to death, and creates more dead cells, thus promoting cancer." This is not a description of side effects. It is a description of the primary action of each therapy.

When chemotherapy enters the body, it does not selectively target cancer cells. It cannot. It is a cytotoxic agent, meaning it is toxic to cells, most cells, all the cells it reaches in adequate concentration. Aajonus put the ratio starkly: for every one cancer cell killed by chemotherapy, approximately one billion healthy cells are killed. For every one cancer cell burned by radiation, approximately one hundred million healthy cells are burned. These are not contested figures in principle. The dose-dependent cellular toxicity of chemotherapy is the reason for every symptom patients experience during treatment: the hair loss, the nausea, the immunosuppression, the damage to kidney and bladder function, the destruction of the intestinal lining, the neurological damage. These are not mysteries. They are the documented consequences of administering a substance that kills cells to a body that runs on cells.

In Aajonus's framework, the consequence of this cellular genocide is direct and predictable. The body already had a problem: an excess of dead cellular matter that it could not dissolve and remove. Chemotherapy introduces a vastly larger quantity of dead cellular matter, because every cell the drug kills becomes dead tissue that must now be processed. The body's lymphatic system, its bacterial workforce, its solvent-producing cancer cells, all of the mechanisms it was using to address the original tumor burden, are now overwhelmed by an iatrogenic flood of new cellular debris. The result, Aajonus documented from his clinical practice, is not resolution of the cancer. It is systemic distribution of new tumor-forming material throughout the body. "You cannot expect to put a poison in the body chemotherapy and expect to get rid of cancer logically, sensibly and rationally. Because the poison destroys the cells, the dead cells remain because your body doesn't have the nutrients or the ability to dissolve these dead cells, so you develop tumors, cancer."

The three months of chemotherapy Aajonus himself endured after ten weeks of radiation therapy produced, in sequence: complete paralysis from the pectorals down, the loss of all hair, systemic vomiting and diarrhea severe enough to confine him to a hardwood floor because any movement of his spine produced what he described as excruciating pain that ran from the tailbone to the brain stem, kidney and bladder damage that left him likely incontinent for life, psoriasis, wounds that would not close, lymphoma as a new diagnosis on top of the multiple myeloma the radiation had already caused. He entered the medical system at age fifteen with a stomach ulcer. He left with stomach cancer, multiple myeloma, and lymphoma. Nobody carrying all three of those diagnoses simultaneously had lived more than three months. He was the only person who survived, and he survived not because of the treatment but because he eventually stopped the treatment and began eating raw animal foods. The body that had been subjected to the equivalent of ten thousand X-rays and three months of systemic cellular poisoning spent the next several decades slowly excreting pharmaceutical compounds, including AZT, a refrigeration fuel that had been repurposed as an anti-cancer agent and was subsequently banned the year after it was used on him as too dangerous. Forty years later, his body was still processing treatment-derived chemicals out through the skin, the urine, the cerebrospinal fluid.

The spine analogy Aajonus used for radiation was not metaphorical. He described what ten weeks of intense radiation therapy did to his spinal column using the example of clay being fired in a kiln: before firing, clay is malleable and permeable; after firing, it becomes rigid, impermeable, dense, unchanging. That transformation is not reversible. "Well, that's what they did to my spine from the radiation therapy. They cauterized my spine." For the next six or seven years after treatment, every movement produced pain that radiated the full length of his back. Not because of the tumor, which had existed before treatment. Because the radiation that was meant to stop the tumor had converted living, functional spinal tissue into something closer to fired ceramic.

Radiation works by damaging the DNA of cells so severely that they cannot replicate. In cancer cells, this prevents them from dividing further. In the several hundred million healthy cells per cancer cell that receive the same dose, it also prevents replication, permanently. Cells that cannot replicate cannot repair damaged tissue. Cells that cannot replicate cannot be replaced when they die. The irradiated zone becomes a permanent dead zone in the terrain, a region where healing cannot occur, where regeneration cannot occur, where the body's maintenance mechanisms cannot operate. New dead tissue accumulates there because the cells that would normally clear debris cannot function. The terrain in the irradiated region is not restored by treatment. It is permanently compromised.

The fact that radiation causes cancer is not a controversial claim within oncology. It is documented in the standard literature, visible in the leukemia rates among atomic bomb survivors, visible in the elevated thyroid cancer rates among populations exposed to medical neck radiation, visible in what happened to Aajonus's own bone marrow. The radiation intended to stop the tumor at his surgical incision site reached his entire spine because the machine was swept across the full spinal column. It deteriorated the bone, dangled his teeth from his gums, and converted healthy bone marrow into the degenerating environment that produced multiple myeloma. The doctors treating him said, without evident irony, "now we have to give you chemotherapy." One intervention had produced the condition requiring the next intervention. The patient entered the system with one problem and was now being treated for four distinct malignancies, all iatrogenic, all attributable to the treatments he had received.

The pharmaceutical procedural manuals that govern oncology, written by the pharmaceutical companies that manufacture the treatments, contain no entry for "cure" and no entry for "heal" except in the context of surgical wounds closing. This is not an oversight. It reflects the actual conceptual architecture of modern oncology, which does not operate within a framework of terrain restoration or systemic health. It operates within a framework of measurable markers: cell counts, tumor size on imaging, circulating antigens. When those markers fall below the threshold of clinical significance, the patient is in remission. When they stay below that threshold for five years, the patient is cured.

What this framework cannot measure, because it does not attempt to measure it, is the state of the underlying terrain. After chemotherapy and radiation, the lymphatic system has been damaged, the microbiome has been largely destroyed, the body's bacterial workforce has been killed by cytotoxic agents, the fat reserves that would normally bind and transport dissolved tumor material are depleted, and the immune architecture has been suppressed to the point where many patients require ongoing pharmaceutical support simply to maintain baseline function. The absence of detectable cancer markers in this environment does not mean the terrain has been restored. It means the terrain has been altered so severely that neither the body nor the cancer can operate normally within it. The patient's resources are consumed by surviving the treatment rather than completing the healing that the tumor formation represented.

Aajonus noted the clinical pattern with particular clarity when discussing patients who came to him after completing oncological treatment. "People get better than they were. They start surviving. All of their nutrient counts go up. Their blood normalizes and the doctors are thrilled and all of this. But they've been so damaged with chemo and radiation and surgeries that their bodies just cannot recover." The recovery trajectory for post-treatment patients was longer, harder, and less certain than for patients who had refused treatment entirely. Hardin B. Jones, emeritus professor of medical physics and physiology at the University of California Berkeley, had documented exactly this pattern in population-level data: patients who refused all cancer therapy lived an average of twelve and a half years after diagnosis. Patients who accepted surgery, chemotherapy, or radiation lived an average of three years. Jones took this data before Congress and before the California Senate and argued that chemotherapy, radiation, and surgery for cancer should be stopped. The pharmaceutical and medical industry responded by contesting his methodology. The data was never successfully refuted. The treatments continued.

Among surveyed oncologists, Aajonus noted, three of every four reported that they would refuse chemotherapy for themselves because of its devastating effects, and would not allow family members to receive it either. The treatment they were professionally obligated to prescribe as standard of care was not the treatment they would choose for their own bodies. The internal contradiction here is not subtle.

The cancer treatment industry generates approximately $280,000 per patient in revenue at current rates, a figure Aajonus documented from his research, compared to $160,000 when he was treated in the 1960s. The pharmaceutical industry's annual revenue from chemotherapy alone runs to hundreds of billions of dollars. A patient who reverses cancer through nutritional intervention, never returns to the oncology clinic, and requires no ongoing pharmaceutical support generates no revenue within this system. A patient who undergoes chemotherapy, develops new toxicity requiring additional treatment, enters partial remission, relapses with metastatic disease, and cycles through multiple rounds of additional treatment generates revenue at every step.

It is worth saying directly that this structural incentive does not require individual malice. Individual oncologists are operating within a system that was designed, from its procedural manuals to its research funding to its regulatory approval pathways, by the pharmaceutical industry. The medical books used in every hospital are written by pharmaceutical companies. The word "heal" appears in those books ninety-three times, always in reference to surgical wounds and abrasions, never in reference to disease resolution. The word "cure" does not appear at all. A physician trained within that system and practicing according to those manuals is not treating cancer in the way that the term "treatment" implies, that is, as an attempt to restore the patient to functional health by addressing the cause of the condition. The physician is executing a pharmaceutical protocol designed to suppress measurable markers of disease while generating the maximum defensible utilization of pharmaceutical products. Whether individual practitioners understand this or not, the structure of the system produces the outcome reliably.

The argument here is not that every patient who accepts chemotherapy or radiation is making a foolish choice. In cases where a tumor is actively obstructing an airway, compressing the spinal cord, blocking the digestive tract, or impeding blood flow to critical structures, emergency intervention may be the only available option for preserving immediate function. Aajonus acknowledged this explicitly: surgery should be considered "only if tumor blocks breathing, digestion, urination, or defecation." The critique is not of emergency debulking in genuinely obstructive cases. It is of the routine protocols that treat every tumor as a threat to be attacked immediately, that remove lymph nodes as a precaution rather than a necessity, that administer chemotherapy to patients with early-stage cancers where spontaneous resolution or nutritional intervention would almost certainly produce equivalent or superior outcomes with none of the iatrogenic damage.

The five-year survival improvement that oncology uses to defend the record of modern cancer treatment deserves scrutiny. The improvement is real, but its source is contested. A significant portion of it is attributable to lead-time bias: earlier detection means the clock starts earlier, so survival from detection to death appears longer even if the disease course is identical. A portion is attributable to the reclassification of conditions as "cancer" that would previously not have been treated at all, including low-grade prostate abnormalities, ductal carcinoma in situ in the breast, and thyroid microcarcinomas that the body would typically contain without intervention. When Morgan and colleagues stripped away these confounders and asked what chemotherapy specifically contributed to five-year survival across twenty-two cancer types, the answer was 2.3 percent. Many patients who appear to survive cancer treatment are surviving despite it, not because of it.

A genuinely informed choice about cancer treatment requires understanding what each intervention does to the terrain, what problem the tumor was attempting to solve in the first place, and what the body needs to complete that process rather than be interrupted mid-course. Raw nutrition, fat loading sufficient to bind and transport dissolved tumor material, restoration of lymphatic function, and supported detoxification take years. They produce not the temporary absence of measurable markers but a fundamental restoration of the body's capacity to process dead cellular material without forming new tumors to contain it. The difference between remission and that kind of restoration is the difference between managing a symptom and addressing its source. One generates ongoing pharmaceutical revenue. The other does not.

If the medical approach to cancer destroys the terrain further, and if the body's own mechanism (the cancer cell as solvent) is the actual healing response, then the question becomes: how do you support the body's process? What does the body need to dissolve dead tissue, restore lymphatic function, and complete the detoxification that tumor formation represents?